Search the Newsreel

Does BioMarin’s Raised 2026 Outlook and ESOP Shelf Offering Reshape the Bull Case for BMRN?

Earlier this month, BioMarin Pharmaceutical reported second-quarter 2026 results showing revenue of US$989.71 million and updated earnings guidance for the second half and full year, including a slight increase in its 2026 revenue outlook to US$3.88 billion–US$3.93 billion. Alongside these results, BioMarin filed a …

Occidental Petroleum stock holds steady as analysts see upside and oil stays elevated

Occidental Petroleum (OXY) stock is trading in the high-$50s, with analysts forecasting a double-digit upside due to elevated oil prices and strong sector profits. The company's financials are robust, with the energy sector showing significant profit growth year-over-year. Technical indicators suggest a "Buy" signal, …

HC Wainwright Issues Pessimistic Forecast for TRAX Earnings

HC Wainwright Issues Pessimistic Forecast for IPSC Earnings

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

* Citius Pharmaceuticals press release [https://seekingalpha.com/pr/20620155-citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides] (CTXR [https://seekingalpha.com/symbol/CTXR]): Q3 GAAP EPS of -$0.34 misses by $0.09. * Revenue of $1.5M misses by $8.27M. * Cash and cash equivalents of $17.0 million as of June 30, 2026. MORE ON CITIUS PHARMACEUTICALS * Seeking Alpha’s Quant …

Valeura Energy: Low Debt, Healthy Oil Pricing

Valeura Energy Stock: Low Debt, Healthy Oil Pricing (OTCMKTS:VLERF)

Scribe Therapeutics (SCTX) Stock Analysis Report | Financials & Insights

What's Going On With Medicenna Therapeutics Corp Stock Sunday?

Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History

Hindustan Petroleum And Bharat Petroleum Stocks In Focus As Oil Price Risk Returns

BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration

Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044

Vanda Pharmaceuticals is set to launch BYSANTI in the second half of 2026 following FDA approval for bipolar I disorder and schizophrenia, with patent protection extending until May 2044. The company also reported strong Q2 Fanapt sales growth and has several late-stage pipeline readouts …

Piraeus Port Authority (HAM:PZE) Shiller PE Ratio : (As of Aug. 16, 2026)

Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics (GLUE) reported widening net losses for Q2 and the first half of 2026, marking a significant shift from prior-year profitability. This financial downturn, with a net loss of US$87.9 million for the six-month period, deepens the investment risk, highlighting the company's …

Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next

Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong second-quarter 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increase signals management's confidence in XDEMVY's commercial trajectory, though the company still faces risks associated …

Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf Filing - Has The Bull Case Changed?

Bank Leumi le-Israel B.M (TASE:LUMI) Following Its Digital Asset Push And The Valuation Case

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Bank Leumi le-Israel B.M (TASE:LUMI) has drawn fresh attention after announcing a partnership with Galaxy Digital to offer digital asset trading to retail customers through its Leumi …

Dianthus Therapeutics (DNTH) Is Up 6.5% After Unveiling DNTH312 Amid Wider Q2 Losses

Johnson & Johnson Purchases New Stake in Rapport Therapeutics, Inc. $RAPP

State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR

The State of Wyoming acquired a new position of 11,780 shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) valued at approximately $1.35 million during the second quarter. This comes as Kymera reported stronger-than-expected quarterly results with a significant revenue increase, although insiders sold a substantial amount …

BioMarin Pharmaceutical (BMRN) Updates Guidance And Files Shelf Registration, Is It Still Below Fair Value?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the …

Euronet director Thomas McDonnell buys $55,138 in company stock

Euronet Worldwide director Thomas McDonnell recently purchased 781 shares of the company's common stock for $55,138. This transaction increased his direct holdings to 101,000 shares, aligning with the company's aggressive share buyback strategy. The purchase follows Euronet's second-quarter results, where adjusted earnings and revenue …

Ocular Therapeutix (OCUL) Is Up 9.2% After Wider Q2 Loss and New US$81.7M Shelf Registration

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

USA Financial Formulas has acquired a new stake in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 1,457 shares valued at approximately $1.13 million, making it their 27th-largest portfolio holding. Institutional investors collectively own 83.31% of Regeneron, with several major firms significantly increasing their positions. The company recently …

Oppenheimer Asset Management Inc. Invests $5.87 Million in Keurig Dr Pepper, Inc $KDP

Oppenheimer Asset Management Inc. recently acquired a new stake of 179,480 shares in Keurig Dr Pepper, Inc (NASDAQ:KDP), valued at approximately $5.87 million during the second quarter. This move is part of broader institutional investment trends, with other major firms like Vanguard Group Inc. …

23,257 Shares in Corcept Therapeutics Incorporated $CORT Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP recently acquired a new position of 23,257 shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the second quarter, valued at approximately $2.022 million. Other institutional investors have also adjusted their holdings in CORT, with 93.61% of the stock owned by hedge …

Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding?

11,096 Shares in Marathon Petroleum Corporation $MPC Bought by Centric Wealth Management

Centric Wealth Management recently purchased 11,096 shares of Marathon Petroleum Corporation (MPC), valued at approximately $2.8 million, marking a new position for the firm. This comes as Marathon Petroleum reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating among …

HighTower Advisors LLC Sells 34,826 Shares of Occidental Petroleum Corporation $OXY

HighTower Advisors LLC reduced its stake in Occidental Petroleum Corporation by 5.1% in the second quarter, selling 34,826 shares. Despite this, other hedge funds increased their holdings, and institutional investors collectively own 88.70% of the company's stock. Occidental Petroleum reported strong Q2 earnings, increased …

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE